Shares of OPKO Health, Inc. (NASDAQ: OPK - Get Free Report) have received a consensus recommendation of "Hold" from the six brokerages that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and one has

OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.

OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.

OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.

HCA Healthcare (NYSE: HCA - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Valuation and Earnings This table compares HCA Healthcare

MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A.

Connor Clark and Lunn Investment Management Ltd. acquired a new stake in OPKO Health, Inc. (NASDAQ: OPK) in the undefined quarter, according to the company in its most recent filing with the SEC. The fund acquired 412,051 shares of the biotechnology company's stock, valued at approximately $618,000. Connor Clark and Lunn Investment Management

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.